AZN Receives US FDA Approval for Klygefa to Treat Adult Generalised Myasthenia Gravis
· The NYC Memo
AstraZeneca announced that the U.S. Food and Drug Administration approved Klygefa (gefurulimab) for the treatment of generalised myasthenia gravis in adult patients. The regulatory decision was supported by results from the PREVAIL Phase III trial demonstrating statistically significant improvements in activities of daily living sustained through one year.
Klygefa is the first dual-binding nanobody C5 inhibitor approved in the U.S., administered once weekly via a subcutaneous autoinjector.